In addition to bisphosphonates, which represented the standard of care for MBD during the last two decades, the RANKL inhibitor, denosumab, was approved in January 2018 for patients with active MM, providing a safe alternative to bisphosphonates in case of compromised renal function. The gene discussed is TNFSF11; the disease is Miyoshi myopathy.